Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The use of the protein uk114 for the treatment and the prevention of chronic active hepatitis

A technology of active hepatitis, 1.UK114, which is applied in the application field of UK114 protein in the treatment and prevention of chronic active hepatitis, and can solve the problems of no prevention and treatment of chronic active hepatitis, low immunity, etc.

Inactive Publication Date: 2004-06-02
ZETESIS SPA
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, no prophylaxis is available except for delayed treatment with corticosteroids or cyclosporin A (which can cause a variety of side effects and can induce immunosuppression, thereby favoring the replication of hepatitis virus, if present). and treatments for chronic active hepatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0011] Male Balb / c mice aged 6 to 8 weeks were injected intraperitoneally with 30 micrograms of UK114 (in 100 μl PBS1), 24 hours and 1 hour later with 20 mg / kg ConA administered intravenously (group A). Control mice (Group B) were treated with 100 μl of PBS following the same experimental procedure as that used for UK114. Another group of mice was injected with PBS instead of ConA (group C). Mice were sacrificed 8 hours after ConA administration, and blood samples were collected from each animal to evaluate alanine aminotransferase (ALAT) levels. At the same time, livers were taken for histological examination in hematoxylin / eosin.

[0012] As shown in the table below, unlike PBS, intravenous administration of ConA induced a significant increase in ALAT plasma levels. Histological examination of the liver revealed a severe lymphomonocytic infiltration. Prophylactic treatment with UK114 largely prevented the rise in serum transaminases. Consistent with these data, histologi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of the protein UK114, also known as MSP 14, for the preparation of medicaments for the treatment or the prophylaxis of chronic active hepatitis.

Description

technical field [0001] The present invention relates to the use of UK114 protein (also known as MSP14) in the preparation of medicine for treating chronic active hepatitis. Background technique [0002] Chronic active hepatitis is inflammation of the liver, especially the portal vein space, accompanied by substantial damage and necrosis of the hilar region, clinically characterized by evolutionary attacks, with obvious body decline, subjaundice, and weight loss, with a long course and leading to hilar Fibrosis or cirrhosis. Two different forms of the disease are known, classified as moderately or severely developing chronic hepatitis, depending on whether the lesion activity is high or low. The severity of inflammation and necrosis as well as clinical and humoral signs observed on liver biopsy can reflect the degree of activity. The disease occurs in both males and females, generally in the 40s / 60s. [0003] The cause of chronic active hepatitis is still unknown. However...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P43/00
CPCA61K38/1709A61P43/00A61K38/17
Inventor A·巴尔托雷利P·尼科莱蒂A·帕内拉伊
Owner ZETESIS SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com